Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

@article{Cummings2010RecombinantLS,
  title={Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.},
  author={James F. Cummings and Michele D. Spring and Robert J. Schwenk and Christian F. Ockenhouse and Kent E. Kester and Mark E. Polhemus and Douglas S. Walsh and I H Yoon and Christine M. Prosperi and Laure Y Juompan and David E. Lanar and Urszula Krzych and Brian T Hall and Lisa A. Ware and Virginia Ann Stewart and Jack Williams and Megan Dowler and Robin K Nielsen and Collette J. Hillier and Birgitte K Giersing and Filip Dubovsky and Elissa Malkin and Kathryn M Tucker and Marie-Claude Dubois and Joe D. Cohen and William Ripley Ballou and Donald G Heppner},
  journal={Vaccine},
  year={2010},
  volume={28 31},
  pages={5135-44}
}
Plasmodium falciparum Liver Stage Antigen 1 (LSA-1) is a pre-erythrocytic stage antigen. Our LSA-1 vaccine candidate is a recombinant protein with full-length C- and N-terminal flanking domains and two of the 17 amino acid repeats from the central repeat region termed "LSA-NRC." We describe the first Phase I/II study of this recombinant LSA-NRC protein formulated with either the AS01 or AS02 adjuvant system. We conducted an open-label Phase I/II study. Thirty-six healthy malaria-naïve adults… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Similar Papers

Loading similar papers…